Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy postmenopausal women (45-80 years old) with a diagnosis of osteoporosis~Exclusion Criteria:~* Use of estrogen or hormone replacement therapy~* Use of bisphosphonates, strontium ranelate or denosumab~* Use of parathyroid analogues or other bone metabolic agents~* Medical conditions which might alter bone metabolism~* Any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia~* Impairment of thyroid function

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PTH analog tablet (Type: EXPERIMENTAL): PTH(1-31) 5 mg tablet, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching tablet, once daily
- Forsteo (Type: ACTIVE_COMPARATOR): Forsteo (teriparatide) 20 mcg SC Injection, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).